Literature DB >> 35223649

COVID-19 Associated Mucormycosis and Anbarnesa: Concerning about Important Source of Spores.

Mohsen Pourazizi1, Rasoul Mohammadi2, Bahareh Abtahi-Naeini3.   

Abstract

Entities:  

Year:  2022        PMID: 35223649      PMCID: PMC8837871          DOI: 10.18502/ijph.v51i1.8320

Source DB:  PubMed          Journal:  Iran J Public Health        ISSN: 2251-6085            Impact factor:   1.429


× No keyword cloud information.

Dear Editor-in-Chief

Simultaneously with the pandemic of coronavirus disease 2019 (COVID-19), several cases of COVID-19-associated mucormycosis (CAM) were reported. The possible explanation for these rare infections in post COVID-19 period can be attributed to the several factors including newer variants (Delta variant) of virus, acute hyperglycemia, ketoacidosis, immune dysregulation following severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) infection, iron metabolism disturbance and etc. (1). Currently, India is one of most prevalent foci of CAM. In addition, CAM was reported in several other countries including USA, Pakistan, Syria, Brazil and Iran (2). Previously, mucormycosis was considered as a rare opportunistic infection in Iran. During a period of 25-year in Iran, less than 100 cases was reported. In the fifth wave of COVID-19 during the summer and fall of 2021, CAM has seen a surge in Iran (3). In one hand, some of CAM cases occurred in healthy individuals without confirmed classic risk factors of mucormycosis, and in the other hand most of reports are from limited countries. Therefore, it seems that in addition to multifactorial etiology for pathogenesis of CAM, environmental and ecological factors have played a major role. Based on Iranian traditional medicine, “Anbarnesa” (female donkey dung) in either form of fresh or smoke has been used for treatment of various medical conditions including wide range of infectious diseases. Currently there are limited and ambiguous data about efficacy, safety and mechanism of action of Anbarnesa on claimed medical conditions. Moreover, there are some evidences about toxicity of Anbarnesa especially in the form of smoke (4). In recent year’s use of the smoke of Anbarnesa, widely suggested in Iran by traditional healers or non-medical practioner for treatment of various conditions (5, 6). Currently use of Anbarnesa for COVID-19 patients with claim of antimicrobial effect is a pivotal concern in Iran. To date, there is no clinical and experimental scientific data for benefit of Anbarnesa in any form of application to improve the outcome of COVID-19. With this hypothesis that Anbarnesa smoke can be as an environmental important factor in Iranian patients for susceptibility to mucormycosis in post COVID-19 period, we evaluated a sample of Anbarnesa that was used as a form of smoke in one of confirmed case of CAM in Isfahan, Iran in 2021. A suspension of each Anbarnesa was made in sterile saline solution 1:10 (w/v) containing chloramphenicol (0.3 mg/ml) and mixed for 5 min and allowed to settle down for 20 min (Fig. 1a). Five microliters of the supernatant was added to sabouraud glucose agar (Difco, Detroit, MI), and incubated at 30 °C for 5 days (7). Fuzzy colonies were examined microscopically using 10% KOH, and photographed (Fig. 1b). Microscopic feature of the Mucorales after 5 days at 30 °C showing sporangium, sporangiophore, and sporangiospores. In addition to the experimental data, our clinical experiences showed that many patients with CAM were used Anbarnesa in course of SARS-COV2 infection.
Fig. 1:

Experimental evaluation of a sample of Anbarnesa that was used in one of confirmed case of COVID-19-associated mucormycosis. a) Making a suspension of Anbarnesa in sterile saline solution 1:10 (w/v). b) Fuzzy colonies of zygomycetes on sabouraud glucose agar after 5 days at 30 °C. c) Microscopic feature of the Mucorales after 5 days at 30 °C showing sporangium (Black arrows), sporangiophore (blue arrows), and sporangiospores (white arrows)

Experimental evaluation of a sample of Anbarnesa that was used in one of confirmed case of COVID-19-associated mucormycosis. a) Making a suspension of Anbarnesa in sterile saline solution 1:10 (w/v). b) Fuzzy colonies of zygomycetes on sabouraud glucose agar after 5 days at 30 °C. c) Microscopic feature of the Mucorales after 5 days at 30 °C showing sporangium (Black arrows), sporangiophore (blue arrows), and sporangiospores (white arrows) As a conclusion and based on our results, Anbarnesa contains spores of the Mucorales and it can be as an important source of spore inhalation. It is therefore important to be aware of its risks. Although our present knowledge about use of Anbarnesa and CAM is inadequate, due to the medical serious conditions related to CAM, in the interest of consumers’ safety, it is recommended to refuse of Anbarnesa in COVID-19 patients. The experimental and stimulatory laboratory study of this area should be encouraged.
  5 in total

Review 1.  Mucormycosis in Iran: a systematic review.

Authors:  Afsane Vaezi; Maryam Moazeni; Mohammad Taghi Rahimi; Sybren de Hoog; Hamid Badali
Journal:  Mycoses       Date:  2016-02-15       Impact factor: 4.377

Review 2.  Anbarnesa: The Past Tradition, the Future Medicine.

Authors:  Hassan Ali Shafiee; Elham Moravej-Salehi
Journal:  Iran Red Crescent Med J       Date:  2015-12-12       Impact factor: 0.611

3.  Identification of Mucorales isolates from soil using morphological and molecular methods.

Authors:  A Ziaee; M Zia; M Bayat; J Hashemi
Journal:  Curr Med Mycol       Date:  2016-03

4.  Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India.

Authors:  Awadhesh Kumar Singh; Ritu Singh; Shashank R Joshi; Anoop Misra
Journal:  Diabetes Metab Syndr       Date:  2021-05-21

5.  Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1.

Authors:  Mrittika Sen; Santosh G Honavar; Rolika Bansal; Sabyasachi Sengupta; Raksha Rao; Usha Kim; Mukesh Sharma; Mahipal Sachdev; Ashok K Grover; Abhidnya Surve; Abhishek Budharapu; Abhishek K Ramadhin; Abhishek Kumar Tripathi; Adit Gupta; Aditya Bhargava; Animesh Sahu; Anjali Khairnar; Anju Kochar; Ankita Madhavani; Ankur K Shrivastava; Anuja K Desai; Anujeet Paul; Anuradha Ayyar; Aparna Bhatnagar; Aparna Singhal; Archana Sunil Nikose; Arun Bhargava; Arvind L Tenagi; Ashish Kamble; Ashiyana Nariani; Bhavin Patel; Bibbhuti Kashyap; Bodhraj Dhawan; Busaraben Vohra; Charuta Mandke; Chinmayee Thrishulamurthy; Chitra Sambare; Deepayan Sarkar; Devanshi Shirishbhai Mankad; Dhwani Maheshwari; Dilip Lalwani; Dipti Kanani; Diti Patel; Fairooz P Manjandavida; Frenali Godhani; Garima Amol Agarwal; Gayatri Ravulaparthi; Gondhi Vijay Shilpa; Gunjan Deshpande; Hansa Thakkar; Hardik Shah; Hare Ram Ojha; Harsha Jani; Jyoti Gontia; Jyotika P Mishrikotkar; Kamalpreet Likhari; Kamini Prajapati; Kavita Porwal; Kirthi Koka; Kulveer Singh Dharawat; Lakshmi B Ramamurthy; Mainak Bhattacharyya; Manorama Saini; Marem C Christy; Mausumi Das; Maya Hada; Mehul Panchal; Modini Pandharpurkar; Mohammad Osman Ali; Mukesh Porwal; Nagaraju Gangashetappa; Neelima Mehrotra; Neha Bijlani; Nidhi Gajendragadkar; Nitin M Nagarkar; Palak Modi; Parveen Rewri; Piyushi Sao; Prajakta Salunkhe Patil; Pramod Giri; Priti Kapadia; Priti Yadav; Purvi Bhagat; Ragini Parekh; Rajashekhar Dyaberi; Rajender Singh Chauhan; Rajwinder Kaur; Ram Kishan Duvesh; Ramesh Murthy; Ravi Varma Dandu; Ravija Kathiara; Renu Beri; Rinal Pandit; Rita Hepsi Rani; Roshmi Gupta; Ruchi Pherwani; Rujuta Sapkal; Rupa Mehta; Sameeksha Tadepalli; Samra Fatima; Sandeep Karmarkar; Sandeep Suresh Patil; Sanjana Shah; Sankit Shah; Sapan Shah; Sarika Dubey; Saurin Gandhi; Savitha Kanakpur; Shalini Mohan; Sharad Bhomaj; Sheela Kerkar; Shivani Jariwala; Shivati Sahu; Shruthi Tara; Shruti Kochar Maru; Shubha Jhavar; Shubhda Sharma; Shweta Gupta; Shwetha Kumari; Sima Das; Smita Menon; Snehal Burkule; Sonam Poonam Nisar; Subashini Kaliaperumal; Subramanya Rao; Sudipto Pakrasi; Sujatha Rathod; Sunil G Biradar; Suresh Kumar; Susheen Dutt; Svati Bansal; Swati Amulbhai Ravani; Sweta Lohiya; Syed Wajahat Ali Rizvi; Tanmay Gokhale; Tatyarao P Lahane; Tejaswini Vukkadala; Triveni Grover; Trupti Bhesaniya; Urmil Chawla; Usha Singh; Vaishali L Une; Varsha Nandedkar; Venkata Subramaniam; Vidya Eswaran; Vidya Nair Chaudhry; Viji Rangarajan; Vipin Dehane; Vivek M Sahasrabudhe; Yarra Sowjanya; Yashaswini Tupkary; Yogita Phadke
Journal:  Indian J Ophthalmol       Date:  2021-07       Impact factor: 1.848

  5 in total
  2 in total

1.  Father-Son COVID-19-associated mucormycosis: Important role of genetic susceptibility in combination with environmental factors.

Authors:  Mohsen Pourazizi; Bahram Eshraghi; Roya Azad; Kimia Afshar; Iman Mohammadbeigy
Journal:  Clin Case Rep       Date:  2022-09-08

2.  From Bilateral Periorbital Necrotic Wound to Fungal Brain Abscess: A Complicated Case of COVID-19-Associated Mucormycosis.

Authors:  Bahram Eshraghi; Nastaran-Sadat Hosseini; Rasoul Mohammadi; Seyed Hamid Reza Abtahi; Alireza Ramezani-Majd; Roya Azad; Mohsen Pourazizi
Journal:  Case Rep Infect Dis       Date:  2022-08-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.